Program
Anti-CD38 Monoclonal Antibody SCTC21C
Its studies are mostly in Lupus Erythematosus, Systemic · Amyloidosis · Multiple Myeloma · Glomerulonephritis, IGA · Hematologic Neoplasms, led by Sinocelltech Group.
Furthest: phase 3, since Dec 3, 20255 company-led studies, 5 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 55 open or running | phase 3since Dec 3, 2025 | Jan 31, 2024 | Apr 2027phase 2 · NCT07538154 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 31, 2024First study: phase 1 study in RecurrenceFirst studyNCT06252298 · 74 planned · China
- Jan 2, 2025Phase 2 study in Glomerulonephritis, IGANCT06774664 · 99 planned · China
- Dec 3, 2025Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07297329 · 292 planned · China
- Jan 28, 2026Phase 3 study in AmyloidosisNCT07388602 · 90 planned · China
- Apr 12, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07538154 · 159 planned
Ahead
- Apr 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07538154
- Sep 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT06774664
- Dec 2027Primary completion: phase 3 study in AmyloidosisNCT07388602
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT07297329
TargetBeta
CD38 →read by rule
“A monoclonal antibody that targets the cell surface glycoprotein CD38, ”NCIt, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07538154Lupus Erythematosus, Systemic | 2 | Not yet recruiting | Apr 2027 | 159 |
| NCT07388602Amyloidosis · China | 3 | Recruiting | Dec 2027 | 90 |
| NCT07297329Multiple Myeloma · China | 3 | Recruiting | Dec 2027 | 292 |
| NCT06774664Glomerulonephritis, IGA · China | 2 | Not yet recruiting | Sep 2027 | 99 |
| NCT06252298Recurrence · China | 1 | Recruiting | Aug 28, 2025 | 74 |
How it is read
Names in the registry
- “SCTC21C”, 5 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
- Amyloidosis, 1 study
- Multiple Myeloma, 1 study
- Glomerulonephritis, IGA, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.